Trial Profile
An Observational study to evaluate the Cardiovascular and Oncologic outcomes of Trastuzumab therapy management after a mild left ventricular ejection fraction (LVEF) drop in patients with early breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jun 2017
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Early breast cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 New trial record